Mesoblast Ltd. jumped the most in almost a decade in Sydney trading after the developer of stem-cell therapies agreed to sell a minority stake to U.S.-based Celgene Corp. for A$58.5 million ($45 million).
The stock rose 24 percent to A$3.99, it biggest gain since May 2005.
